Skylock is a Canadian post-seed startup committed to securing the future of DeFi by proactively defending against smart-contract hacks. Recognizing the industry's need for stability, Skylock leverages cutting-edge technology to detect and block malicious transactions in real-time, protecting DeFi protocols and their users. Skylock was founded in 2022 in Ottawa, Canada.
Godmode is the AI-native sales enablement tools. Helps you connect and build with genuine human relationships and proactively finds you leads based on your ideal customer profile and signals on the web.
Tatsumeeko is a Discord-first fantasy massively multiplayer online role-playing game (MMORPG).
Voyage Finance provides Web3 firm decentralized loans for gamers and guilds.
Pollen Mobile provides a decentralized mobile network that is built on the blockchain which is owned and operated by its users. Pollen Mobile helps to build its own mobile connectivity through a crypto-economy, enabling users to have reliable and affordable mobile connectivity.
Polemos is a global Gaming company that has developed advanced proprietary asset management solutions, non-collateralised lending solutions, proprietary learning management systems (LMS), advanced game/player data analytics solutions, and range of gaming focussed media and entertainment assets. Polemos was ideated and launched in early 2020 by five international cofounders that have investment and business interests in strategically aligned industry sectors. Commonly confused as a 'blockchain' business, Polemos delivers solutions to all traditional and emerging strategy gaming verticals. Led by renown global technology executive Richard McLaren, most well known for his roles as Managing Director of Microsoft NineMSN (APAC), Head of MoneySupermarket.com, Global Director at McKinsey and BCG, and as Managing Director of ThoughtWorks, and Hal Crawford - former Chief Editor and Publisher at Microsoft NineMSN, and Global CEO at Mediaworks, the business is expanding rapidly into a large number of globally distributed markets - not dissimilar to those markets pursued by Microsoft for its content business originally. Cofounders of Polemos include: Tom Hall - Former CEO of Playtech and Asian Logic, CEO of Sporting News (https://www.linkedin.com/in/tomhallhk/) - Tom Hall is recognised as a pioneer and one of the world’s leading experts in the field of online gaming software development, specialising in interactive gaming and is a regular key note speaker at investor forums and gaming conferences around the World. Tom is known globally for his role as Co-Founder and CEO of Asianlogic, an Asian-facing gaming group established in 2002. He also led Playtech as Group CEO and oversaw the successful floatation of the Company on the UK AIM market in 2006. Playtech was the world’s largest publicly quoted gaming software provider (UK:PTEC - USD3.5Bn+ Market Cap). Of Eurasian Hong Kong origin, Tom was responsible for overseeing global customer growth and the development of customised software solutions for the Asia Pacific marketplace. He retired in 2020 as Chairman to pursue his interests in the media sector. Previously publicly listed in the UK, ALOG was taken private in 2009 and grew to become one of the Top 10 Global online gaming companies with 2500 staff across 6 countries. Since 2014, Hall has spent most of his time building Pax Holdings Limited, a family office focussed on sports media, fintech, gaming, leisure-related real estate and asset management platform software development. As at 2020, his core focus is Pax’s digital media expansion, most recently leading the acquisition of The Sporting News, www.sportingnews.com, the digital evolution of the US's oldest sports newspaper founded in 1886. He has also recently joined the Board of Leisurerights.com, a newly formed rights management collective. Zac Rosenberg - Managing Partner at Capzed (https://www.linkedin.com/in/zac-rosenberg-079a34/) - Zac co-founded Capital Zed in January 2015. Previously was Managing Director/Head of Investment Banking from 2012 to 2015 at Canaccord Genuity (Melbourne), Managing Director/Head of Investment Banking from 2009 to 2012 at Keefe, Bruyette & Woods (Hong Kong), Managing Director/ Head of Investment Banking at Fox-Pitt, Kelton (Hong Kong) from 2005 to 2009 and Executive Director at CIBC World Markets (Hong Kong/Singapore) from 2000 to 2005 His current Board roles include Mobi2Go (New Zealand), The Influential Network (USA), Predictive Hire (Australia), Fresho (Australia), Campaign Agent (Australia), as well as several private investment companies and vehicles. Zac holds a Bachelor of Commerce from Monash University. Darren Smorgon - Managing Director of Sandbar Investments (https://www.linkedin.com/in/darren-smorgon-20214713/) - Darren is Managing Director of Sandbar Investments, a Sydney based family office with investments in private equity, equities, property and alternative investments including venture capital and crypto currency. Until 2015, Darren was a Director, member of the advisory board and partner at CHAMP Private Equity where he was responsible for portfolio companies including oOh!media, Study Group, Golding Contractors and LCR Group. Darren is currently Chairman of Hub Australia, Non Executive Director of Total Drains Group and Swift Networks, Co-Founder and Non Executive Director of Arrowpoint Capital. He is also actively involved in several philanthropic activities including as a member of the Allocations Committee of the JCA and the Chairman of Nextthink. Kevin O’Hara - Managing Director of Sentor Investments and Partner at Trivian Capital Management (https://www.linkedin.com/in/kevino23/) - Kevin has an extensive history as an investor and founder. In 2005 Kevin founded OCTIEF Group (Acquired by IHG and Tulla Private Equity) and in 2010 Kevin founded the OCTFOLIO SaaS based Enterprise Governance, Risk and Compliance Management (eGRCM) Solution (acquired by HRL and ALS Global Limited). Kevin has an MBA with a major in Digital Transformation and Business Intelligence and is currently Managing Director of Sentor Investments, Venture Partner at SDGx Climate Technology Fund, Venture Partner and IC Member at Primal Capital and IC Member at Newzone Ventures in Portugal. Scott Plowman - Managing Director of Mozaik Capital (https://www.linkedin.com/in/scottplowman/) - Scott is the Managing Director of Mozaik Capital based in Singapore, Co-Founder of Polemos.io, acting DAO Key Controller for the Polemos DAO, and Foundation Partner and Investor in Herradura Ventures. Mozaik Capital is most well known as one of the original Venture focussed Web3 investors, with multiple exits across Axie Infinity, Algorand, DFinity, STEPN, Yield Guild and Kava to name a few. In the web3 investing space, Scott is known for the establishment and management of large scale project validator and node structures, including for the Algorand protocol in 2018.. Today Scott is also actively involved at the foundation level of numerous technology companies. Scott’s background is in the establishment, administration and portfolio management for numerous large-scale funds and financial services organisations, and in high level technical/quantitative market analysis and derivatives trading.
Crypto Raiders is a highly-interactive dungeon crawler game built on the blockchain. Players have the ability to buy characters and mobs, go on missions, build teams in a virtual universe all while discovering NFTs they then own. Crypto Raiders is built on the Polygon blockchain, and all NFT loot is randomized, ensuring that the value of all discovered loot is random as well.
Initial Coin Offering in 2022
Crypto Unicorns is a Web3 game development and research and development studio.
MetalCore is a maker of computer games. They provide services for fighting games. They provide products that include mechs, infantry, aircraft, and vehicles.
Squads is a developer of a decentralized program that enables the establishment of better and easier decentralized autonomous groups. The company's application combines all of the key components of a decentralized autonomous organization, such as deployment, treasury, vault management, on-chain voting, and chat, into a single portal with an easy-to-use interface, allowing users to streamline daily operations using a decentralized autonomous organization structure.
Jambo is building the world's largest on-chain mobile network powered by the JamboPhone — the most powerful crypto-native mobile device. We have built this vision through support of top investors including Paradigm, Pantera, OKX, Coinbase, and more. With Jambo's hardware foundation of 800,000+ mobile nodes across 120+ countries, Jambo and our Ecosystem partners can achieve decentralization faster and more cost-effectively. Network effects can be achieved instantly for use cases including validators, P2P networking, and other new products. Jambo has onboarded millions into the on-chain economy through the JamboApp which features: - Innovative earning and airdrop opportunities - Jambo Ecosystem dApp store - JamboWallet multi-chain wallet Jambo is transforming lives in all corners of the world particularly in emerging markets by creating the hub for users to secure next generation blockchain use cases while earning real rewards. At the heart of the Jambo economy is the Jambo Token, a utility token fueling rewards, discounts, payouts, and more. Powering the decentralized future.
DOOMSDAYX is a creative technology studio for web3 artists and fans, focused on redefining culture on-chain.
Hubble is a decentralized financial protocol that allows for long-term borrowing, lending, and structured products.
Friktion Labs is a team of quantitative traders, researchers, and crypto engineers with backgrounds in commodities, treasuries, volatility products, and crypto-assets. The organization has brought on board a group of derivatives traders and market makers in Genesis Trading, Alameda Research, LedgerPrime, QCP Capital, CMS Holdings, Orthogonal Trading, and GSR.
Suberra provides products that help businesses accept crypto payments and innovates to enhance the user experience for crypto payments. Their services include accepting crypto payments for commerce, one-time payments, and subscriptions.
Hubble is a decentralized financial protocol that allows for long-term borrowing, lending, and structured products.
Beta Finance is a permissionless money market protocol for lending, borrowing, and short-selling crypto assets. It aims to offset crypto volatility and bring market stability. Its one-click solution enables traders without technical know-how to manage and update their short positions on any token with all relevant token information directly available on the interface to guide their decision.
LayerZero Labs is a company focused on blockchain interoperability, providing a protocol that connects decentralized applications (dapps) across different blockchains. Its platform enhances data exchange by utilizing an on-chain light node for validation, which streamlines the process of handling block headers. Instead of storing all block headers in sequence, LayerZero employs decentralized oracles to deliver block headers on demand. This approach not only increases speed and security but also improves cost efficiency, enabling clients to develop cross-chain applications with a simple communication framework. Through its innovative technology, LayerZero aims to facilitate seamless interactions between diverse blockchain networks.
Tessera's mission is to curate the most extraordinary collective ownership experiences produced by the greatest creators, builders, and leaders. Tessera's vision is a world where anyone can have the opportunity to collectively own and govern things they value, without reliance on central gatekeepers to execute decisions and actions on their behalf.
Pontem Network is a product studio building the first-ever suite of foundational dApps for Aptos. Pontem Wallet, the secure and powerful wallet for Aptos, is available for Chrome, Mozilla Firefox, iOS and Android. Use Pontem Wallet to store and send any tokens on Aptos. The wallet is integrated with our Liquidswap DEX, the first DEX and AMM for Aptos, Topaz and Souffl3 NFT marketplaces, Ditto and Tortuga liquid staking platforms, Argo and Aries lending protocols, and all other major Aptos dApps. Our other products include the browser code editor Move Playground, the Move IntelliJ IDE plugin for developers, and the Solidity-to-Move code translator ByteBabel – the first ever implementation of the Ethereum Virtual Machine for Aptos.
Bright Star Studios, is a global independent games development studio crafting next generation original MMO game franchise experiences using it’s own proprietary engine. We are led by a diverse team of award-winning venture founders, former world champion pro-players and entertainment professionals who come with decades of game industry experience. We are innovators who are carving a new path forward for MMORPGs across PC, Browser, and Mobile. The studio’s mission is to rewrite the games industry with a business model that favors the community through exciting competitive gameplay, instant playability and a leading platform which supports the player economy. The studio is working on their flagship MMORPG title, Ember Sword, a modern rewrite of the games industry business model which brings a player-owned economy and the community together in a unique and engaging cooperative role playing universe. www.EmberSword.com www.BrightStar.Studio.com
Fractal is a financial technology company that provides digital assets and blockchain adoption services. They also develop tools for institutional investors to access decentralized financing.
Fully permissionless protocol for decentralized perpetual swaps
Covalent is the leading modular data infrastructure layer dedicated to solving major challenges in blockchain and AI, including verifiability, decentralized AI inference, and Long-Term Data Availability. Its large reservoir of structured, verifiable data enhances decentralized training and inference, reducing the risk of manipulated or biased AI models. Additionally, the Covalent Network's Ethereum Wayback Machine ensures secure, decentralized access to Ethereum’s transaction data. Trusted by over 3,000 leading organizations, Covalent powers AI, DeFi, GameFi, and more with unfettered access to on-chain data from over 225 blockchains. Learn about the EWM: Technical | Non-Technical For more information, check out Covalent’s: Official Website | Twitter/X | Linktree
One wallet for all your crypto. XDEFI is a non-custodial wallet that allows you to securely swap, store, and send NFTs and crypto across 30 blockchains. Join more than 200,000 people that trust XDEFI Wallet!
Anchor Protocol is a savings platform that provides crypto natives, fintech companies, and investors a stable, high interest rate finance. The company was founded in 2020 and is headquartered in Seoul, South Korea.
Armor develops a dynamic cover brokerage protocol for decentralized finance to serve cryptocurrency investors. Founded in 2021, Armor is a DeFi coverage aggregator that makes securing your DeFi assets against hacks as easy as possible. Ease wants to make DeFi as easy and safe as possible. They aim to cover every dollar in DeFi so that users can finally feel at ease.
Caravan Wellness provides corporate wellness programs, online education solutions, social media campaigns, impact tracking, exclusive digital content, brand partnerships, cross industry partnerships, influencers, affiliates, success, nutrition, wellness, yoga, meditation, fitness, productivity, confidence, results, sleep, mindfulness, and employee wellness.
LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). Our solutions enable customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain. The company develops cost-effective perception solutions scalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types (camera, radar and LiDAR) and configurations. LeddarTech’s disruptive technology reduces risks, accelerates development cycles and enables faster time-to-market. We are responsible for several cutting-edge remote-sensing innovations, with over 140 patents granted or applied for that enhance ADAS and autonomous driving capabilities. Our customers are OEMs and Tier 1-2 automotive suppliers looking for sensing and perception solutions that allow them to meet their key performance, cost and development time requirements for faster time-to-market and ROI.
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California.
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California.
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.
Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.
ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.
Private Equity Round in 2013
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.
Labcyte Inc. is a laboratory instrumentation company with a novel approach to dispensing small volumes of liquids for life sciences applications. The company's acoustic dispensing technology uses a focused beam of acoustic energy to eject nanoliter-scale droplets of fluid from one plate to another, with high accuracy at low volumes and reduced consumables costs. In addition to DBL Investors, investors include Alloy Ventures, Abingworth, New Leaf Venture Partners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Tandem diabetes care provides products that empower both people with diabetes and those who care for them. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges.
Relypsa is a biotech company. They discover and develop non-absorbed polymeric drugs for applications in cardiovascular and renal diseases. They specialize in iron deficiency, nephrology, and cardio-renal therapies.
Private Equity Round in 2012
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Private Equity Round in 2012
Relypsa is a biotech company. They discover and develop non-absorbed polymeric drugs for applications in cardiovascular and renal diseases. They specialize in iron deficiency, nephrology, and cardio-renal therapies.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Pivot Medical is a privately held medical device company focused on developing and marketing novel technologies for a rapidly growing segment of the orthopedic marketplace. The advancements currently on the market and in development by our company hold great promise for those active persons seeking minimally invasive treatments.
Relypsa is a biotech company. They discover and develop non-absorbed polymeric drugs for applications in cardiovascular and renal diseases. They specialize in iron deficiency, nephrology, and cardio-renal therapies.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California.
Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.
PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.
ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. These electro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life.
NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.
Relypsa is a biotech company. They discover and develop non-absorbed polymeric drugs for applications in cardiovascular and renal diseases. They specialize in iron deficiency, nephrology, and cardio-renal therapies.
NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer's disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
BÂRRX Medical, Inc. develops endoscopic treatment solutions for Barrett's esophagus and other chronic gastroenterological diseases. Barrett's is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. The company's HALOFLEX, HALO360 and HALO90 ablation systems are designed to provide a uniform and controlled ablation effect, in order to remove diseased tissue and allow re-growth of normal cells. A multi-center randomized, sham-controlled study, published in the New England Journal of Medicine in 2009, studied HALO radiofrequency ablation applied in the highest risk Barrett's population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased rate of disease progression and cancer development, as compared to the control group. In another study (AIM-II) published in Gastrointestinal Endoscopy, 98.4% of treated patients were Barrett's-free after two and a half years of follow-up. The HALO systems are cleared by the FDA for use in the United States and each have CE Mark for use in Europe. More than 58,000 procedures have been performed in over 400 hospitals around the world. Based in Sunnyvale, Calif., BÂRRX Medical, Inc. was founded in 2000 and is privately-held.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
Breathe Technologies, Inc was founded in 2005 with the objective of empowering healthcare providers and patients with new, reliable and accessible respiratory therapies that optimize breathing and mobility. They are in the process of developing truly ultra-light, compact, patient-friendly ventilator systems that can transform respiratory care in the hospital and home markets.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.
Tandem diabetes care provides products that empower both people with diabetes and those who care for them. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges.
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared
Primaeva Medical is a privately held venture capital funded company developing devices for dermatologists, plastic surgeons and other cosmetic/aesthetic physicians. Primaeva Medical is dedicated to providing the aesthetic physician superior new tools for Restoring Youth for their patients who want to reverse the signs of aging. In 2009 Primaeva will introduce a groundbreaking fractional radiofrequency system designed for the predictable treatment of aging skin.
SynergEyes®, Inc. was founded in 2001 with a recognized need for a hybrid contact lens that combined the superior visual acuity of a rigid gas permeable lens with the comfort of a soft contact lens. The revolutionary SynergEyes® hybrid contact lens allows you to enjoy the best of both worlds - a stable, high oxygen permeable rigid center that delivers consistent, crisp, clear vision while the outer skirt gives you all the all-day comfort of a soft lens.
Acclarent, Inc. is a medical device company. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools—Balloon Sinuplasty® devices. Through the Balloon SinuplastyTM technology and the company's RelievaTM registered product portfolio, we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005, and the products were commercially launched in the US that same year.
ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. These electro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life.
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cellsâ€. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.
Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.
ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. These electro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life.
Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.
At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.